A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
Clinical trial NCT06192576 · RECRUITING
Trial details
- NCT number
- NCT06192576
- Sponsor
- Sanofi
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-04-16
- Primary completion
- 2029-01-02
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.